AJ Vaccines Holding ApS - Group

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  10.4% 8.8% 7.4% 8.9% 3.7%  
Credit score (0-100)  25 28 31 27 51  
Credit rating  BB BB BB BB BBB  
Credit limit (mDKK)  -0.0 -0.0 -0.0 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  323 362 368 423 469  
Gross profit  -225 -312 -245 -64.0 -30.7  
EBITDA  -329 -428 -451 -228 -207  
EBIT  -329 -428 -451 -228 -207  
Pre-tax profit (PTP)  -362.0 -384.2 -721.9 -520.1 -293.0  
Net earnings  -362.0 -384.2 -721.9 -519.3 -293.4  
Pre-tax profit without non-rec. items  -329 -428 -451 -520 -293  

 
See the entire income statement

Balance sheet (mDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 665 676  
Shareholders equity total  -331 -717 -1,189 -1,238 929  
Interest-bearing liabilities  0.0 0.0 0.0 2,341 143  
Balance sheet total (assets)  1,846 1,735 1,451 1,485 1,512  

Net Debt  0.0 0.0 -23.6 2,256 137  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  323 362 368 423 469  
Net sales growth  -10.7% 12.0% 1.6% 15.0% 10.8%  
Gross profit  -225 -312 -245 -64.0 -30.7  
Gross profit growth  -49.0% -38.8% 21.3% 73.9% 52.0%  
Employees  719 722 558 575 577  
Employee growth %  5.1% 0.4% -22.7% 3.0% 0.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,846 1,735 1,451 1,485 1,512  
Balance sheet change%  32.1% -6.0% -16.4% 2.3% 1.8%  
Added value  -328.6 -427.8 -450.7 -228.0 -206.9  
Added value %  -101.6% -118.1% -122.4% -53.9% -44.1%  
Investments  0 0 0 925 -15  

Net sales trend  -1.0 1.0 2.0 3.0 4.0  
EBIT trend  -3.0 -4.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  -101.6% -118.1% -122.4% -53.9% -44.1%  
EBIT %  -101.6% -118.1% -122.4% -53.9% -44.1%  
EBIT to gross profit (%)  146.4% 137.3% 183.7% 356.0% 673.4%  
Net Earnings %  -111.9% -106.1% -196.1% -122.7% -62.6%  
Profit before depreciation and extraordinary items %  -111.9% -106.1% -196.1% -122.7% -62.6%  
Pre tax profit less extraordinaries %  -101.6% -118.1% -122.4% -122.9% -62.5%  
ROA %  -18.4% -18.5% -17.7% -8.5% -6.6%  
ROI %  -18.4% -18.5% -17.7% -8.7% -6.9%  
ROE %  439.5% 73.3% 75.8% -291.1% -23.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% -44.1% 59.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 643.5% 124.2%  
Relative net indebtedness %  0.0% 0.0% -6.4% 623.4% 123.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 5.2% -989.8% -66.3%  
Gearing %  0.0% 0.0% 0.0% -189.1% 15.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 25.0% 12.4%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 0.1 0.6  
Current Ratio  0.0 0.0 0.0 0.2 2.4  
Cash and cash equivalent  0.0 0.0 23.6 84.9 6.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 50.1 90.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 6.4% 132.4% 128.3%  
Net working capital  0.0 0.0 23.6 -1,887.3 345.7  
Net working capital %  0.0% 0.0% 6.4% -446.0% 73.7%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 1 1 1 1  
Added value / employee  -0 -1 -1 -0 -0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -0 -1 -1 -0 -0  
EBIT / employee  -0 -1 -1 -0 -0  
Net earnings / employee  -1 -1 -1 -1 -1